An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design by Herst, C. V. et al.
An Effective CTL Peptide Vaccine for Ebola Zaire
Based on Survivors' CD8+ Targeting of a Particular
Nucleocapsid Protein Epitope with Potential
Implications for COVID-19 Vaccine Design
Herst CVa, Burkholz Sa, Sidney Ji, Sette Ai, Harris PEg, Massey Sb, Brasel
Tb, Cunha-Neto Ec,d,e, Rosa DSd,f, Chao WCHj, Carback Ra, Hodge Ta,
Wang La, Ciotlos Sa, Lloyd Pa,
Rubsamen Ra,h,∗
aFlow Pharma, Inc., 3451 Vincent Road, Pleasant Hill, CA 94523
bUniversity of Texas, Medical Branch,301 University Blvd, Galveston, TX 77555
cLaboratory of Clinical Immunology and Allergy-LIM60, University of Sa˜o Paulo School of
Medicine, Sa˜o Paulo, Brazil
dInstitute for Investigation in Immunology (iii) INCT, Sa˜o Paulo, Brazil
eHeart Institute (Incor), School of Medicine, University of Sa˜o Paulo, Sa˜o Paulo, Brazil
fDepartment of Microbiology, Immunology and Parasitology, Federal University of Sa˜o
Paulo (UNIFESP/EPM), Sa˜o Paulo, Brazil
gEndocrinology Division, Department of Medicine, School of Medicine, Columbia
University, New York, New York, USA
hMassachusetts General Hospital, Department of Anesthesia, Critical Care and Pain
Medicine, 55 Fruit St, Boston, MA 02114
iLa Jolla Institute for Allergy and Immunology, 9420 Athena Circle La Jolla, CA 92037
jUniversity of Macau, E12 Avenida da Universidade, Taipa, Macau, China
Abstract
The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak
to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors
showed that 26 of those individuals had a CD8+ response to at least one EBOV
protein. The dominant response (25/26 subjects) was specific to the EBOV
nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV
NP could form an important part of an effective T-cell vaccine for Ebola Zaire.
We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a
conserved region of EBOV NP provides protection against morbidity and mor-
tality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6
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mouse using an adjuvanted microsphere peptide vaccine formulation containing
NP44-52 is enough to confer immunity in mice. Our work suggests that a pep-
tide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually
sound and feasible. Nucleocapsid proteins within SARS-CoV-2 contain multiple
class I epitopes with predicted HLA restrictions consistent with broad popula-
tion coverage. A similar approach to a CTL vaccine design may be possible for
that virus.
Keywords: Ebola Zaire vaccine, CTL Vaccine, controller, YQVNNLEEI,
COVID-19, SARS-CoV-2, Flow Focusing
1. Introduction
Development of safe and effective vaccines for some viruses such as HIV and
EBOV has been challenging [19]. Although vaccine development has been al-
most exclusively focused on eliciting a humoral immune response in the host
through inoculation with whole protein antigen [51][69][59][29], CTL peptide5
vaccines producing a T-cell response may offer an important alternative ap-
proach [23]. For HIV and EBOV and influenza in particular, the potential
of CTL vaccines has been discussed [21][7][56]. Although computational pre-
diction alone has been used for T-cell vaccine design [2][14], we saw a unique
opportunity to see if a preventative EBOV T-cell vaccine could be successfully10
designed based on the specific epitopes targeted by survivors of documented
EBOV infection.
The notion of HLA restricted HIV control has been described [58]. Pereyra-
Heckerman conducted an analysis of virus-specific CD8+ T-cell immunity in
individuals living with HIV [43]. They reported that HIV controllers, individuals15
living with HIV not undergoing treatment who do not progress to AIDS, have
CD8+ cells targeting different HLA restricted class I epitopes on HIV compared
with progressors, individuals with HIV who progress to AIDS in the absence of
therapy. Pereyra-Heckerman suggested that this observation could guide the
in-silico development of a CTL vaccine for HIV and other diseases.20
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Acquired immunity has been documented after EBOV infection [4]. Anti-
body as well as T-cell responses have been described [44]. Sakebe et al. have
shown that of 30 subjects surviving the 2013-2016 EBOV outbreak in West
Africa, CD8+ T-cells from 26 of those survivors responded to at least one
EBOV antigen, with 25 of the 26 responders targeting epitopes on EBOV NP25
[50]. One of the most commonly targeted EBOV eptitopes on EBOV NP in
the survivor group (targeted by CD8+ cells from four survivors) was NP41-60
(IPVYQVNNLEEICQLIIQAF). They also suggested that a CTL vaccine could
be designed using epitopes targeted by CD8+ T-cells identified in these EBOV
controllers.30
Human pathogen-derived peptide antigens that are also recognized by C57BL/6
T-cells have been previously described. These include peptides from vesicular
stomatitis virus (VSV) RGYVYQGL [68], and human immunodeficiency virus
(HIV) RGPGRAFVTI [5]. The existence of such epitopes makes a range of pre-
clinical vaccine experiments possible without having to rely on non-human pri-35
mates and expensive and complex-to-manage humanized mouse models. Wilson
et al. showed that the EBOV nucleoprotein (NP) is an immunogen that pro-
vides protective, CTL-mediated immunity against EBOV in a C57BL/6 mouse
model and that this protection was conferred by a peptide sequence within Ebola
Zaire: NP43-53 (VYQVNNLEEIC) [73]. Wilson et al. came to this conclusion40
based on studying splenocytes harvested from mice vaccinated with Ebola Zaire
NP using a Venezuelan equine encephalitis (VEE) vector. Their experiments
showed that splenocytes from the vaccinated mice re-stimulated with NP43-53
had high levels of cytotoxic activity against target cells loaded with the EBOV
NP peptide. Remarkably, NP43-53 also happens to be an 11 amino acid sub-45
sequence of the epitope identified by Sakebe et al. as most commonly favored
for T-cell attack by survivors of the 2013-2016 EBOV outbreak in West Africa.
We set out to see if we could drive CTL expansion directed against NP43-53
to occur after vaccinating C57BL/6 mice with Ebola Zaire NP43-53 (VYQVNNLEEIC),
and to subsequently conduct an in-vivo EBOV challenge study to see if this pep-50
tide was protective.
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We fabricated adjuvanted microspheres for this study as a room temperature
stable dry powder using the Flow Focusing process to be 11µM in diameter so
as to prevent more than one microsphere from being phagocytosed by any given
antigen presenting cell (APC) at the same time [37]. By loading only one peptide55
sequence per microsphere, we maximized the peptide payload and mitigated the
possibility of multiple, different peptide sequences being delivered to the APC
simultaneously, which could possibly result in competitive inhibition at the motif
which could interfere with antigen presentation and subsequent T-cell expansion
(Supplementary Material Section 1).60
We also set out to see if a similar approach to a CTL vaccine design for SARS-
CoV-2 would be feasible based on an analysis of the HLA binding characteristics
of peptide sequences on SARS-CoV-2 nucleocapsid.
2. Results
We used a previously described biodegradable dry powder, PLGA micro-65
sphere, synthetic vaccine platform adjuvanted with TLR-4 and TLR-9 agonists
for this study [48]. In that article, we showed that the TLR-4 and TLR-9 ag-
onists given together with a peptide in a mouse model did not produce T-cell
expansion by ELISPOT and that microencapsulation of the peptide and the
TLR-9 ligand, with the TLR-4 ligand in the injectate solution, was required to70
elicit an immune response to the delivered peptide antigen as determined by
ELISPOT. That study also demonstrated that the microencapsulated peptides
alone were insufficient to induce an adequate immune response without the pres-
ence of the TLR-4 and TLR-9 agonists administered as described. The TLR
agonists used for this vaccine formulation are used in FDA approved vaccines75
and can be sourced as non-GMP or GMP material for pre-clinical and clinical
studies.
We show here that the H2-Db restricted epitopes VSV (RGYVYQGL) and
OVA (SIINFEKL), when administered to C57BL/6 mice, each produce a CD8+
ELISPOT response to the administered peptide antigen with no statistically80
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significant CD4+ response measurable by ELISPOT as shown in Figure 2c, and
Figure 2d.
We used this adjuvanted microsphere peptide vaccine platform to immunize
C57BL/6 mice with NP43-53, the CTL+ class I peptide antigen from the Ebola
Ziare NP protein identified as protective by Wilson et al. [73]. Microspheres85
containing NP43-53 and CpG were prepared as a dry powder formulation and
suspended before use in a PBS injectate solution containing MPLA, and admin-
istered intradermally via injection at the base of the tail into mice as described
in a previous publication [48]. As illustrated in Figure 1c, there was no statisti-
cally significant difference between the ELISPOT data for the vaccinated mice90
versus the response seen in the negative ELISPOT controls.
Wilson reported that protection seen in her experiment was due to a pep-
tide sequence within NP-43-53. We hypothesized that the NP43-53 epitope
was inefficiently processed into MHC binding sub-sequences during antigen pre-
sentation. In order to explore possible H2-Db matches for peptide sequences95
contained within Ebola Zaire NP43-53 (VYQVNNLEEIC), we prepared three
peptide vaccine formulations, each containing one of the three possible 9mer
sub-sequences within NP43-53. These sequences are shown in Table 1. We
then vaccinated, via intradermal (tail) injection, three groups of mice with mi-
crospheres containing one of the three 9mer sub-sequences of NP43-53 (6 per100
group). ELISPOT analysis was performed, stimulating harvested splenocytes
with the three possible 9mer sub-sequences. Splenocytes from mice receiving
the NP44-52 sub-sequence had a statistically higher ELISPOT response than
mice vaccinated with the other two possible sub-sequence 9mers (P < 0.0001)
as shown in Figure 1a. This is consistent with the predicted H2-Db binding105
affinity of YQVNNLEEI as shown in Supplementary Material Table 3.
We then loaded one population of adjuvanted microspheres with NP44-52
and a second population of adjuvanted microspheres loaded with VG19 from
EBOV Zaire NP 273-291 (VKNEVNSFKAALSSLAKHG), a Class II epitope
predicted to be relevant to NP43-53 based on the TEPITOPE algorithm using110
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9mer Sub-sequences of VYQVNNLEEIC
Evaluated for Immune Response
Peptide Label Peptide Sequence Description
NP43-53 VYQVNNLEEIC Ebola Zaire NP 11mer peptide not H2-Db matched
NP43-51 VYQVNNLEE Sub-sequence 9mer VYQVNNLEEIC
NP44-52 YQVNNLEEI Sub-sequence 9mer VYQVNNLEEIC
NP45-53 QVNNLEEIC Sub-sequence 9mer VYQVNNLEEIC
Table 1: Class I peptides used in the study. NP43-53 is the class I 11mer described by Wilson
et al. which we found not to produce an immune response in a C57BL/6 mouse model.
NP43-51, NP 44-52 and NP 45-53 are the three possible 9mer sub-sequences of NP43-53.
a technique described by Cunha-Neto at al [14]. This peptide has a predicted
favorable H2-Ib binding affinity as shown in Supplementary Material Table 5.
We showed that vaccination of 6 mice with the adjuvanted microsphere vac-
cine loaded with VG19 and NP44-52 showed an ELISPOT response to NP44-52
whereas 6 mice vaccinated with adjuvanted microspheres not loaded with pep-115
tide did not (Figure 1d).
We also showed that mice vaccinated with VG19 alone did not show an
ELISPOT response to NP44-52 (Figure 2a) and, conversely, mice vaccinated
with NP44-52 did not show a response to VG19 (Figure 2b).
We conducted a pilot study demonstrating that intraperitoneal injection of120
the adjuvanted microsphere vaccine produced a statistically superior immune
response by ELISPOT compared with the same dose delivered by intradermal
tail or intramuscular injection in C57BL/6 mice (Supplementary Material Sec-
tion 2). Based on the data from that study, and the fact that the volume of
the intraperitoneal space would allow larger amounts of microsphere suspension125
to be delivered, we chose to proceed with intraperitoneal administration for the
challenge portion of this study delivering 20mg of microspheres per dose.
We dosed three groups of mice, ten mice per group, with the adjuvanted mi-
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crosphere vaccine formulation containing NP44-52 and VG-19, with each peptide
in a distinct microsphere population, and challenged these mice 14 days after130
vaccine administration with escalating IP administered doses of mouse adapted
EBOV (maEBOV) (Group 3 - 100 PFU, Group 5 - 1000 PFU and Group 7 -
10,000 PFU). The composition of the vaccine used for the exposure study is
described in Supplementary Material Section 3. A second set of three control
groups of mice (groups 2, 4 and 6), ten mice per group (mock groups), received135
PBS buffer solution alone and served as control animals for the study and were
similarly challenged with maEBOV. Group 1 animals served as study controls
and received no PBS buffer, vaccine or maEBOV injections. All mice were
sourced from Jackson Labs and were 6-8 weeks of age and 15-25 grams at the
time of vaccination. The dosing regimen is outlined in Table 2.140
Peak mortality across all groups tested was seen in mice challenged with
1,000 PFU maEBOV versus PBS buffer control as shown in the survival curve in
Figure 3a. Clinical observation data shown in Figure 3b and Figure 3c and daily
weight data shown in Figure 3d and Figure 3e show protection from morbidity
in all active vaccinated mice exposed to 1,000 PFU maEBOV.145
PBS buffer mock-vaccinated mice showed mortality increasing from the 100
PFU to 1,000 PFU as shown in Figure 4a and Figure 3a. We saw a paradoxical
effect in control animals with survival increasing between 1,000PFU (Figure 3a)
and 10,000 PFU (Figure 5a). We believe this was caused by innate immunity
triggered by the very large maEBOV challenge. All mice in all vaccinated150
groups across both experiments survived and showed no morbidity by clinical
observation scores and weight data.
For each of the three challenge levels, the difference between the number of
survivors in the vaccinated group versus the PBS control group was statistically
significant by chi square (100 PFU P = 0.001; 1000 PFU P = 0.0003; 10,000155
PFU P = 0.003).
We saw what appears to be an innate immune response at the 10,000 PFU
EBOV exposure level. It has been suggested that EBOV can mediate an innate
immunity response through stimulation of TLR-4 [33]. Because the adjuvanted
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microsphere vaccine used in this experiment incorporates a TLR-4 agonist, we160
dosed 10 mice with adjuvanted microspheres without peptides and found the
level of protection after exposure to 100 PFU EBOV to be statistically no dif-
ferent from that seen in PBS buffer controls (Supplementary Material Figure
1). We conclude that level of protection conferred by the adjuvanted vaccine de-
scribed in this study is dependant on delivering peptides with the microspheres.165
The data in Supplementary Material Figure 1 also shows, in two separate ex-
periments conducted months apart with the same 100 PFU maEBOV challenge
dose and the same (active) vaccine formulation, that the vaccinated animals in
both active groups had 100% survival and no morbidity by clinical observation.
This provides some evidence that the protective effect of vaccination using this170
adjuvanted microsphere vaccine is reproducible.
Serum samples from sacrificed animals exposed to EBOV who did not receive
vaccine were quantitatively assayed for various cytokines using BioPlex plates.
Animals having unwitnessed demise did not have serum samples collected. A
Pearson Correlation Analysis was performed to assess relationships between175
specific cytokine levels and survival. The results are shown in Table 3.
We observed low levels of IL-6 in surviving mice. NHPs infected with EBOV
have been determined by other researchers to have elevated levels of IL-6 in
plasma and serum [27][17]. EBOV infected humans have also shown elevated IL-
6 levels and these elevated levels have been associated with increased mortality180
[71].
Similarly, we observed low levels of MCP-1, IL-9 and GM-CSF in survivors.
Increased serum and plasma levels of MCP-1 have been observed in EBOV
infected NHPs [22][27][17] and elevated levels of MCP-1 were associated with
fatalities in EBOV infected human subjects [71]. Human survivors of EBOV185
have been found to have very low levels of circulating cytokines IL-9 and elevated
levels of GM-CSF have been associated with fatality in humans exposed to
EBOV [71].
We saw increased levels of IFN −γ in survivors. Other vaccine studies have
associated IFN − γ with protection [70][38].190
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We achieved protection against maEBOV challenge with a single injection
of an adjuvanted microsphere peptide vaccine loaded with a class I peptide in a
region on EBOV nucleocapsid favored for CD8+ attack by survivors of the 2013-
2016 West Africa EBOV outbreak. There is evidence that a CTL response could
be beneficial in the context of a coronavirus infection. [13][41][64][11][28][36]195
Peng et al. have found survivors of the SARS-CoV-1 outbreak who had circu-
lating T-cells targeting SARS-CoV-1 nucleocapsid two years after initial infec-
tion. [42] We decided to investigate the feasibility of designing a SARS-CoV-2
peptide vaccine targeting SARS-CoV-2 nucleocapsid.
All available SARS-CoV-2 protein sequences were obtained from the NCBI200
viral genomes resource within GenBank, an NIH genetic sequence database [8].
Retrieved sequences were processed using multiple sequence alignment (MSA)
via Clustal for the nucleocapsid phosphoprotein [34]. The nucleocapsid phos-
phoprotein sequences were trimmed down to every possible peptide sequence
9 amino acids in length. 9mers were chosen because they typically represent205
the optimal length for binding to the vast majority of HLA [1][18][3]. The re-
sulting peptides were compared to the MSA to ensure than these sequences are
conserved within all of the sequencing samples available and not affected by
an amino acid variant that could complicate subsequent analysis, specifically
the calculation of population coverage. A selection of HLA were selected to210
encompass the vast majority of the worlds population at over 97% coverage.
Peptides were run through artificial intelligence algorithms, netMHC and
netMHCpan which were developed using training data from in-vitro binding
studies. The pan variant of netMHC is able to integrate in-vitro data from a
variety of HLA to allow for predictions to be made if limited in-vitro data is215
available for the specified target HLA [30][1]. This in-silico analysis utilizes the
neural networks ability to learn from the in-vitro data and report back pre-
dicted values based on the imputed SARS-CoV-2 nucleocapsid phosphoprotein
peptides. Peptides with a predicted HLA IC50 binding affinity of 500nm or less
in either of the algorithms, were included in the candidate list of targets for the220
vaccine [30][1][40].
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Dosing Table
Vaccinated Animals versus PBS Controls
100, 1000, and 10,000 PFU maEBOV Challenge
Group N Active / Control Formulation Route Challenge
1 4 Control N/A N/A N/A
2 10 Control PBS 400µl IP 100PFU maEBOV
3 10 Active 10mg Adjuvanted Microspheres with NP44-52 400µl IP 100 PFU maEBOV
10mg Adjuvanted Microspheres with VG-19
4 10 Control PBS 400µl IP 1,000PFU maEBOV
5 10 Active 10mg Adjuvanted Microspheres with NP44-52 400µl IP 1,000 PFU maEBOV
10mg Adjuvanted Microspheres with VG-19
6 10 Control PBS 400µl IP 10,000PFU maEBOV
7 10 Active 10mg Adjuvanted Microspheres with NP44-52 400µl IP 10,000 PFU maEBOV
10mg Adjuvanted Microspheres with VG-19
Table 2: C7BL/6 maEBOV challenge study dosing regimen with PBS (buffer) controls. All
challenges were done with Ebola virus M. musculus/COD/1976/Mayinga-CDC-808012 (maE-
BOV) delivered IP. Mice in Group 1 received no injections.
A subset of these SARS-CoV-2 peptide sequences are present on SARS-
CoV-1 nucleocapsid phosphoprotein and as a result had in-vitro binding data in
Immunology Epitope Database and Analysis Resource (IEDB) collected after a
previous outbreak [65]. Predicted values of these peptides were cross referenced225
with actual in-vitro binding measurements from identical 9mer peptides when
that data was available.
3. Summary and Discussion
Most preventative vaccines are designed to elicit a humoral immune response,
typically via the administration of whole protein from a pathogen. Antibody230
vaccines typically do not produce a robust T-cell response. [72] A T-cell vaccine
is meant to elicit a cellular immune response directing CD8+ cells to expand
and attack cells presenting the HLA Class I restricted pathogen-derived peptide
antigen. [47] Difficulty in obtaining a reliable immune response from peptide
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antigens and the HLA restricted nature of CTL vaccines have limited their util-235
ity to protect individuals from infectious disease [77]. However, observations
derived from individuals able to control HIV infection [43] and EBOV infection
[50] demonstrating that control may be associated with specific CTL targeting
behavior, suggest that there may be an important role for HLA-restricted pep-
tide vaccines for protection against infectious disease for which development of240
an effective traditional whole protein vaccine has proved to be difficult. The
adjuvanted microsphere peptide vaccine platform described here incorporates
unmodified peptides making possible rapid manufacture and deployment to re-
spond to a new viral threat.
NP44-52 is located within one of the EBOV nucleocapsid proteins considered245
essential for virus replication. This epitope resides in a sequence conserved
across multiple EBOV strains as shown in Supplementary Material Figure 6.
A 7.3A structure for NP and VP24 is shown for context in Figure 6a [67]. A
1.8A resolution structure rendering for EBOV NP shown in Figure 6b illustrates
that NP44-52 is a buried structural loop, which is likely to be important to the250
structural integrity of the EBOV NP protein [16]. This structural role of NP44-
52 likely explains its conservation across EBOV strains.
CTL targeting of the EBOV NP protein has been described [42][64][28]
[49][24]. Nucleocapisid proteins are essential for EBOV replication [61]. Re-
cent advances in T-cell based vaccines have focused on avoiding all variable255
viral epitopes and incorporating only conserved regions [7][25]. EBOV NP may
be more conserved than nucleocapsid proteins VP35 and VP24 making it more
suitable as a CTL vaccine target [9][73]. The nucleocapsid proteins in SARS-
CoV-1 are also essential for that virus to function normally [10]. This suggests
that a CTL vaccine targeting coronavirus nucleocapsid could be effective against260
SARS-CoV-1 or SARS-CoV-2.
We have shown that an H2-Db restricted Class I peptide exists within the
NP41-60 epitope identified by Sakebe et al. as the most commonly favored NP
epitope for CD8+ attack by survivors of the 2013-1016 EBOV outbreak in West
Africa. We have demonstrated, when delivered in conjunction with a predicted-265
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matched Class II epitope using an adjuvanted microsphere peptide vaccine plat-
form, NP44-52 protection against mortality and morbidity for the maEBOV
challenge doses tested in a C57BL/6 mouse model. We accomplished this with
an adjuvanted, microsphere-based, synthetic CTL peptide vaccine platform pro-
ducing a protective immune response 14 days after a single administration.270
EBOV can cause severe pulmonary problems in exposed subjects [39]. These
problems can be especially severe when the virus is delivered by aerosol [15][31].
Interaction of EBOV specific antibody, NHP lung tissue and EBOV delivered
to NHPs via aerosol can produce a more lethal effect than in NHPs without
circulating anti-EBOV antibody exposed to aerosolized EBOV (unpublished275
conference presentation). This suggests that a CTL vaccine may be more effec-
tive for prophylaxis against filovirus protection than an antibody vaccine if the
anticipated route of EBOV exposure is via aerosol.
Sakebe et al. identified A*30:01:01 as the only HLA type common to all
four survivors in their study with CD8+ targeting of NP41-60. The A*30 su-280
pertype is relatively common in West Africa: 13.3% for Mali, 15.4% for Kenya,
16.3% for Uganda, and 23.9% for Mozambique [32]. Although peptide vaccines
are by their nature HLA restricted, it may be possible to create a CTL vaccine
directed against EBOV for use alone or in conjunction with a whole protein vac-
cine to produce an antibody response in tandem, by incorporating additional285
Class I peptides from epitopes targeted by controllers to broaden the HLA cov-
erage of the vaccine. MHC binding algorithms hosted by the IEDB predict that
YQVNNLEEI will bind strongly to the MHC of HLA-A*02:06, HLA-A*02:03
and HLA-A*02:01 individuals (Supplementary Material Table 2) [65]. HLA-
DR binding database analysis also suggests that VKNEVNSFKAALSSLAKHG290
demonstrates sufficiently promiscuous binding characteristics cover that same
population (Supplementary Material Table 4) [65]. Taken together, a peptide
vaccine based on YQVNNLEEI and VKNEVNSFKAALSSLAKHG could pro-
duce a cellular immune response in about 50% of the population of the Sudan
and about 30% of the population of North America.295
The internal proteins located within influenza virus, in contrast to the gly-
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coproteins present on the surface, show a high degree of conservation. Epitopes
within these internal proteins often stimulate T-cell-mediated immune responses
[57]. As a result, vaccines stimulating influenza specific T-cell immunity have
been considered as candidates for a universal influenza vaccine [66].300
SARS-CoV-1 infection survivors have been found to have a persistent CTL
response to SARS-CoV-1 nucleocapsid two years after infection. [42] This sug-
gests that the same approach could be applied to SARS-CoV-2 which has con-
served regions in nucleocapsid which is located within the virus (see multiple
sequence alignment in Supplementary Material Figure 7 and Supplementary305
Material Figure 8). Antigenic escape allows a virus to retain fitness despite
an immune response to vaccination [20]. Picking conserved regions for vaccine
targeting is an important part of mitigating this problem. Coronavirus spike
protein, for example, may be particularly susceptible to mutation meaning that
antigenic escape would be likely if the spike protein was targeted by a coron-310
avirus vaccine, making it difficult to achieve durable protection. [74] A recent
paper conducted a population genetic analysis of 103 SARS-CoV-2 genomes
showing that the virus has evolved into two major types: L and S, with changes
in their relative frequency after the outbreak possibly due to human intervention
resulting in selection pressure [62].315
We took all possible 424 9mer peptide sequences from the SARS-CoV-2
nucleocapsid protein sequences available and evaluated each peptide for HLA
restriction using NetMHC 4.0 and NetMHCpan 4.0 [65][30][1]. We analyzed
9mer peptide sequences because these are often associated with superior MHC
binding properties than class I peptides of other lengths [63][18]. We found320
53 unique peptides with predicted binding below 500nM from NetMHC 4.0
and/or NetMHCpan 4.0. These results are shown in Supplementary Material
Table 6, Supplementary Material Table 7, Supplementary Material Table 8 and
Supplementary Material Table 9.
We proceeded to determine the predicted HLA population coverage of a325
vaccine incorporating all 53 peptides using median values of the ANN, SMM,
NetMHC 4.0 and NetMHCpan 4.0 algorithms hosted by IEDB [65]. These 53
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peptides, taken together, had predicted HLA coverage of greater than 97% of
the world’s population as shown in Supplementary Material Table 10. We also
calculated HLA coverage based on alleles specific to populations in China and330
found that coverage across those individuals could be expected to be within
3% percent of the world wide coverage estimate as shown in Supplementary
Material Table 11. This same population coverage could be achieved with 16 of
the 53 unique peptides as shown in Table 4.
Seven of the 53 peptides with a predicted HLA match have been tested335
in-vitro for HLA binding affinity by various researchers [65]. These binding
affinity assays were originally performed with the SARS virus during a previous
outbreak. Specific literature references for these in-vitro assays for each pep-
tide sequence are as follows: ASAFFGMSR, LSPRWYFYY, QQQGQTVTK:
[53], FPRGQGVPI: [53][26][46][60], GMSRIGMEV: [26][64][13][41][12], KTF-340
PPTEPK: [53][26][45][60][6] and LLLDRLNQL: [41][13][12][64][78]. These seven
peptides are shown in red in Supplementary Material Table 6 and Supplemen-
tary Material Table 7.
The remaining 46 SARS-CoV-2 peptides listed in could also be further qual-
ified as potential vaccine candidates by confirming MHC binding predictions by345
in-vitro binding affinity and/or binding stability studies [54][52][26]. Another
approach to evaluating the 53 SARS-CoV-2 candidate vaccine peptides though
in-vitro testing is also possible.
As we have shown in this paper, a peptide targeted by EBOV controllers
could form the basis of a preventative vaccine for EBOV. ELISPOT analysis of350
PBMCs taken from the peripheral blood of COVID-19 controllers and progres-
sors to assess the presence of a differential response to the 53 peptides could lead
to a broadly applicable protective CTL vaccine against SARS-CoV-2 by incor-
porating peptides into the vaccine that are more commonly targeted for CD8+
attack by the controllers versus the progressors. A peptide vaccine for SARS-355
CoV-2, unlike a typical antibody vaccine, is not limited to virus surface antigen
targets. This provides opportunities to attack other targets on SARS-CoV-2
besides spike which may be prone to mutation [74].
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In addition, a peptide vaccine mitigates the risk of Antibody Disease En-
hancement (ADE) seen in the context of a non-neutralizing antibody response to360
a whole protein vaccine [75][55]. Also, neutralizing antibodies directed against
spike protein in SARS-CoV-1 patients have been associated with an increased
risk of Acute Lung Injury (ALI)[35]. Specifically, patients succumbing to SARS-
CoV-1 were found to develop a neutralizing antibody (NAb) response to spike
protein faster than survivors after the onset of symptoms and the NAb titers365
were higher in the patients who died compared with those who recovered[76]. To
the extent to which antibody vaccines producing an antibody response against
the spike protein in SARS-CoV-2 could increase the risk of ALI, this risk could
also be mitigated by a using peptide vaccine as an alternative approach.
The extent of the COVID-19 outbreak should allow many more controllers370
to be identified than the thirty individuals studied by Sakabe and the seven
individuals identified in the Peng study [42][50]. Furthermore, Sakebe and Peng
did not report progressor data perhaps because of the difficulty in obtaining
blood samples from those patients. If researchers act now during the COVID-
19 outbreak, perhaps controller and progressor blood samples could be collected375
and prospectively analyzed, quickly creating a database of optimal candidate
class I peptides for inclusion into a CTL vaccine with potentially broad HLA
coverage for subsequent rapid manufacture and deployment. It would be in-
teresting to see the extent to which the peptides favored by controllers appear
on SARS-CoV-2 nucleocapsid, making SARS-CoV-2 a second example, across380
two different viruses, of controllers exhibiting CTL attack preferentially on the
nucleocapsid protein.
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(b) ELISPOT plate negative controls for








ELISPOT Response for Mice Treated with 


















(c) ELISPOT data for 11mer peptide ver-
sus ELISPOT plate negative control.




















ELISPOT Response with NP44-52 and VG-19




(d) ELISPOT data for active microspheres
versus adjuvanted microsphere control.
Figure 1: ELISPOT data from three groups of six mice each. Each of the three groups of
mice were vaccinated (2mg adjuvanted microspheres via ID tail injection) with a different
9mer peptide sub-sequence of NP43-53. ELISPOT data showed NP44-52 produced the best
immune response (1a). Mice vaccinated (2mg adjuvanted microspheres via ID tail injection)
with the NP43-53 11mer produced the same immune response as ELISPOT plate negative
control (1c). The same active formulation administered to mice for the challenge study (20mg
adjuvanted microspheres via intraperitoneal injection) produced a positive immune response
compared with both adjuvanted microsphere and ELISPOT plate controls (1d). (n.s. = not
significant)
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(a) Mice treated with NP44-52 do not show
an immune response to VG19.

























(b) Mice treated with VG19 do not show
an immune response to NP44-52.



























(c) CD8+ response predominates after vac-
cination with OVA class I peptide.


























(d) CD8+ response predominates after vac-
cination with VSV class I peptide.





















ELISPOT Response to VSV and OVA
by Cell Type Negative Controls
(e) Negative controls for ELISPOT re-
sponse to OVA and VSV by cell type.
Figure 2: Six mice treated with NP44-52 (2mg adjuvanted microspheres via ID tail injection)
were evaluated for their ELISPOT response to NP42-52 and VG19 (2a), and another group
of six mice treated with VG19 (2mg adjuvanted microspheres via ID tail injection) have their
ELISPOT responses to NP42-52 and VG19 shown in Figure 2b. In each of these groups, the
mice generated an immune response only to the vaccinated peptide. A group of seven mice was
evaluated for their immune response by cell type (using magnetic bead separation) for their
ELISPOT responses evaluating total, CD8, and CD4 cell populations after vaccination (2mg
adjuvanted microspheres via ID tail injection) with OVA peptide (2c) and VSV peptide (2d).
For both peptides, the immune response by ELISPOT was from the CD8+ cell population.
(n.s. = not significant)
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(a) Post infection survival curves for 1,000 PFU challenged mice comparing mice vac-
cinated with microspheres containing the class I epitope sequence and different mi-
crospheres containing the class II epitope sequence versus PBS buffer control 14 days
before maEBOV challenge. The difference between the number of survivors in the vac-
cinated group versus the PBS control group was statistically significant by chi square
(P = 0.0003).



































1,000 PFU (PBS Control)
(b) Clinical observations (control).



































1,000 PFU (Active Microspheres)
(c) Clinical observations (active).























1,000 PFU (PBS Control) Body Weights 
(d) Daily weights (control).























1,000 PFU (Active Microspheres) Body Weights 
(e) Daily weights (active).
Figure 3: 1000 PFU post-challenge data (20mg active adjuvanted microspheres via intraperi-
toneal injection versus PBS buffer solution) collected beginning 14 days after vaccination.
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(a) Survival curve versus PBS buffer control. The difference between the number
of survivors in the vaccinated group versus the PBS control group was statistically
significant by chi square (P = 0.001).



































100 PFU (PBS Control)
(b) Clinical observations (control).



































100 PFU (Active Microspheres)
(c) Clinical observations (active).























100 PFU (PBS Control) Body Weight
(d) Daily weights (control).























100 PFU (Active Microspheres) Body Weight
(e) Daily weights (active).
Figure 4: 100 PFU post-challenge data (20mg active adjuvanted microspheres via intraperi-
toneal injection versus PBS buffer solution) collected beginning 14 days after vaccination.
33
author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.02.25.963546doi: bioRxiv preprint 
(a) Survival curve versus PBS buffer control. The difference between the number
of survivors in the vaccinated group versus the PBS control group was statistically
significant by chi square (P = 0.003).



































10,000 PFU (PBS Control)
(b) Clinical observations (control).



































10,000 PFU (Active Microspheres)
(c) Clinical observations (active).























10,000 PFU (PBS Control) Body Weights 
(d) Daily weights (control).























10,000 PFU (Active Microspheres) Body Weights
(e) Daily weights (active).
Figure 5: 10,000 PFU post-challenge data (20mg active adjuvanted microspheres via intraperi-
toneal injection versus PBS buffer solution) collected beginning 14 days after vaccination.
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(a) EBOV nucleocapsid proteins NP
and VP24 shown.
(b) NP44-52 is a conserved structural
loop (red) buried inside the NP struc-
ture. The conservation and the loca-
tion of NP44-52 suggest that residues
44-52 are important for the structural
integrity of the EBOV NP.
Figure 6: The class I epitope used for this study is located within NP. Nucleocapsid proteins
NP and VP24 are shown together in (a). A detailed view of NP with the study epitope
position highlighted in shown in (b).
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Cytokine / Survival Correlations for Control Groups
Cytokine p-Value Correlation
Mo IL-6 0.050 Decreased with survival
Mo MCP-1 0.019 Decreased with Survival
Mo IL-9 0.015 Increased with survival
Mo MIP-1b 0.009 Decreased with survival
Mo IL-12(p40) 0.006 Increased with Survival
Mo G-CSF 0.005 Decreased with Survival
Mo IL-1b 0.005 Increased with Survival
Mo IFN-g 0.003 Increased with Survival
Mo GM-CSF 0.002 Increased with Survival
Mo IL-12(p70) 0.001 Increased with Survival
Mo TNF-a 0.001 Increased with Survival
Mo IL-17 0.000 Increased with Survival
Mo IL-10 0.000 Decreased with Survival
Table 3: Cytokines with statistically significant (positive or negative) correlation with survival
in non-vaccinated mice are shown here along with (Pearson Correlation Analysis) p-values.
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SARS-CoV-2 Nucleocapsid Top Candidate Peptides with
Associated Predicted HLA Restricted Binding Affinities
Peptide Start Allele NetMHC 4.0 NetMHCpan 4.0 SARS
Position pIC50nM pIC50nM Same?
LSPRWYFYY 104 HLA-A*01:01 48.64 76.9 YES
LLLDRLNQL 222 HLA-A*02:01 14.81 11.3 YES
KTFPPTEPK 361 HLA-A*03:01 20.8 18.8 YES
KTFPPTEPK 361 HLA-A*11:01 6.8 7.7 YES
KHIDAYKTF 355 HLA-A*23:01 134.12 778.7 YES
YYRRATRRI 86 HLA-A*24:02 74.89 322 NO
NTASWFTAL 48 HLA-A*26:01 1113.04 122.6 YES
IGYYRRATR 84 HLA-A*33:03 N/A 57.8 YES
FPRGQGVPI 66 HLA-B*07:02 3.82 4.7 YES
SPRWYFYYL 105 HLA-B*08:01 13.77 42.1 YES
KAYNVTQAF 266 HLA-B*15:01 40.35 19 NO
RRIRGGDGK 92 HLA-B*27:05 65.94 72.5 NO
NTASWFTAL 48 HLA-B*39:01 47.87 353.3 YES
MEVTPSGTW 322 HLA-B*44:02 11.48 14.2 YES
LPNNTASWF 45 HLA-B*53:01 19.03 25.7 YES
KAYNVTQAF 266 HLA-B*58:01 12.51 17.7 NO
KAYNVTQAF 266 HLA-C*03:04 N/A 12.7 NO
YRRATRRIR 87 HLA-C*07:01 112.27 8786.2 NO
QRNAPRITF 9 HLA-C*07:02 112.27 237.8 NO
FAPSASAFF 307 HLA-C*08:01 N/A 280.1 YES
Table 4: This set of 16 unique peptides represents the minimum number required to achieve
> 95% world-wide population coverage. The starting position is within the nucleocapsid. Top
binding affinity predictions chosen via NetMHC 4.0 or NetMHCpan 4.0. Peptide sequences
colored in red have literature references as known in-vitro binders to the predicted allele match
(see text).
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